Scribe Therapeutics, Inc.
SCTX evidence brief
What we can confirm
- BioSniper Score:
- 6.0 / 10
- Market Cap:
- $571.2M
- Lead Asset:
- stx-1150
What it means
What to watch
Prepared research question
What matters most for SCTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SCTX
Scribe Therapeutics (SCTX) is a pre-revenue, clinical-stage genetic medicine company developing CRISPR-based therapies for cardiometabolic diseases, with a lead program (STX-1150) in LDL-C lowering and preclinical programs targeting Lp(a) and triglycerides.
Key risk: No approved products
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$571.2M
Cash Runway
—
Lead Asset
stx-1150
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates for Scribe Therapeutics, Inc..
Scribe Therapeutics (SCTX) is a pre-revenue, clinical-stage genetic medicine company developing CRISPR-based therapies for cardiometabolic diseases, with a lead program (STX-1150) in LDL-C lowering and preclinical programs targeting Lp(a) and triglycerides.
- Lead program STX-1150 is in clinical development for potent and persistent LDL-C lowering [sec · filed 2026-07-20].
- Preclinical programs STX-1200 (Lp(a)) and STX-1400 (triglycerides) have shown >90% target gene reduction in mouse models and >95% Lp(a) reduction in NHPs [sec · filed 2026-07-20].
- Cash & equivalents of $35.6M as of 2026-06-30 [sec]; net loss of -$6.5M and shareholders' equity of -$164.8M for the same period [sec].
- Company acknowledges it will need substantial additional funding to advance R&D, clinical trials, and commercialization [sec · filed 2026-07-20].
- Key scientific founders include CRISPR pioneer Dr. Jennifer Doudna (non-employee, non-director) and Dr. Brett Staahl [sec · filed 2026-07-10].
What works
- Proprietary ELXR and XE technologies enable durable, one-time genetic editing with high on-target efficacy and no detectable off-target editing in preclinical studies [sec · filed 2026-07-20].
- Pipeline addresses large cardiometabolic markets (LDL-C, Lp(a), triglycerides) with high unmet need [sec · filed 2026-07-20].
- Company has assembled a team of leaders in genetic medicines, including a world-renowned scientific advisory board [sec · filed 2026-07-10].
What to weigh
- Company has no approved products and no product revenue; future success depends entirely on advancing candidates through clinical trials and regulatory approval [sec · filed 2026-07-20].
- Cash position of $35.6M (as of 2026-06-30) is limited relative to the substantial funding needed for clinical development, manufacturing, and commercialization [sec · filed 2026-07-20].
- Shareholders' equity is deeply negative (-$164.8M as of 2026-06-30), reflecting accumulated losses and capital structure challenges [sec].
- Dr. Doudna, a key scientific figure, is not expected to become an employee or director, which may limit ongoing operational involvement [sec · filed 2026-07-10].
From the filings
Quoted directly from source documents.
Preclinical programs show high efficacy in animal models.
“prototype versions of both STX-1200 and STX-1400 programs have achieved greater than 90% reduction in target gene expression with durable effect consistent with a one-time treatment profile.”
SEC filings · July 20, 2026
Risks & what to watch (4)›
Key risks
- No approved products — Company has no product revenue; all candidates are in clinical or preclinical stages [sec · filed 2026-07-20].
- Cash runway limited — Cash of $35.6M (2026-06-30) may be insufficient to complete clinical development without additional funding [sec].
- Negative equity — Shareholders' equity of -$164.8M indicates accumulated losses exceed capital [sec].
- Key founder not operational — Dr. Doudna, a key scientific figure, will not be an employee or director post-offering [sec · filed 2026-07-10].
What to watch
- Clinical progress of STX-1150 in LDL-C lowering trials [sec · filed 2026-07-20].
- Initiation of clinical trials for STX-1200 and STX-1400 [sec · filed 2026-07-20].
- Company's ability to secure additional funding given limited cash and negative equity [sec].
- Regulatory updates and manufacturing scale-up for genetic medicines [sec · filed 2026-07-20].
Sources: SEC filings · Generated September 29, 2026 · How we verify sources →
Run Scribe Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Scribe Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$6M
No tracked pipeline phase
3 candidates
No upcoming catalysts tracked
9 buys · 0 sells (180d)
Pipeline
Financials
Frequently asked questions
What is the AI investment thesis for Scribe Therapeutics, Inc.?
Scribe Therapeutics (SCTX) is a pre-revenue, clinical-stage genetic medicine company developing CRISPR-based therapies for cardiometabolic diseases, with a lead program (STX-1150) in LDL-C lowering and preclinical programs targeting Lp(a) and triglycerides.
Who is the CEO of Scribe Therapeutics, Inc.?
Dr. Benjamin L. Oakes Ph.D. is the chief executive officer of Scribe Therapeutics, Inc. (SCTX).
Where is Scribe Therapeutics, Inc. headquartered?
Scribe Therapeutics, Inc. (SCTX) is headquartered in Alameda, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.